Full-Time

Director/Senior Director Clinical Development

Remote

Confirmed live in the last 24 hours

Roivant Sciences

Roivant Sciences

201-500 employees

Develops biopharmaceuticals and RNA therapeutics

Biotechnology
Healthcare

Senior

New York, NY, USA

Office located at 151 West 42nd Street, 15th Floor, New York, NY 10036.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Google Cloud Platform
Requirements
  • MD or MD/PhD
  • 5+ years clinical development experience in a pharmaceutical/biotech company and ideally 2+ years in a lead development role.
  • Experience designing and executing first-in-human through registration-enabling clinical programs.
  • Experience in both US and outside US (OUS) development preferred.
  • Can integrate precision medicine and partner to develop a robust translational medicine strategy.
  • Technical, operational and managerial experience in planning, executing, reporting and publishing clinical studies.
  • Proven ability to work independently and to lead a multidisciplinary trial team in a complex matrix environment. Experience in developing effective relationships with key investigators.
  • Thorough knowledge of GCP, clinical trial design, statistics, regulatory processes, and global clinical development process.
  • Advanced knowledge of immunology and inflammation is preferred.
Responsibilities
  • Hands-on responsibility designing and executing clinical trials, in addition to developing and implementing clinical strategies.
  • Lead the project scientists, ensuring appropriate training, mentoring, and supervision across the assigned study/studies within the clinical development program.
  • Work closely with functional partners (Biostatistics, Regulatory, Clinical Operations etc.) to ensure an integrated and strategic approach to flawless execution and systematic oversight of study protocol(s).
  • Responsible for understanding the regulatory requirements related to the clinical studies and global drug development and accountable for complying with those requirements; may serve as a clinical representative for key regulatory discussions.
  • Assume medical responsibility for clinical trials including active participation in real-time medical monitoring of studies, including patient eligibility assessment, study design questions, accrual, and safety data review.
  • Primary point of contact for medical inquiries from sites, CRO and site monitors; answer or triage questions as appropriate integration of clinical/regulatory/manufacturing strategy into global product development strategy.
  • Responsible for assessment and reporting of serious adverse events per corporate policy and regulations for those protocols on which assigned.
  • Ensures adherence to Good Clinical Practices, pharmacovigilance standards, standard operating procedures and to all other quality standards in conducting research.
  • Work with external collaborators, including CROs and other external academic or industry partners.
  • Support the creation of and/or review of clinical slides for internal and external meetings (e.g. Investigator Meetings, SIVs, Advisory Boards, Steering Committee Meetings, etc.)
  • Assist or lead in authoring key clinical study documents, including Protocols, Clinical Study Reports, Investigator Brochures, Regulatory Authority briefing books, Development Safety Update Reports etc.
  • Evaluate medical rationale in new potential assets or indications, discuss proof-of-concept and registration trial designs with external experts.
  • May review/co-author medical publications emerging from clinical trial results.
  • Manage direct reports based on need.

Roivant Sciences develops and delivers medicines and technologies aimed at improving patient health, focusing on drug candidates for genetic disorders and RNA therapeutics. The company operates by maximizing the potential of these candidates through a combination of in-house development and strategic partnerships, which helps build a strong pipeline of drugs. One of its key subsidiaries, Genevant, specializes in RNA therapeutics, utilizing proprietary delivery platforms for mRNA, RNAi, and gene editing to create effective treatments for specific diseases. Roivant generates revenue through drug development, licensing agreements, and partnerships, with the goal of bringing innovative treatments to market efficiently.

Company Stage

IPO

Total Funding

$1.8B

Headquarters

New York City, New York

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-11%
Simplify Jobs

Simplify's Take

What believers are saying

  • Roivant's recent $7.1B deal with Roche to acquire Telavant highlights its strong potential for lucrative partnerships and significant financial growth.
  • The company's diverse pipeline, including promising RNA therapeutics and gene editing technologies, offers substantial opportunities for breakthrough treatments.
  • Strategic investments, such as the $2.02 million from Exchange Traded Concepts LLC, indicate strong investor confidence and financial stability.

What critics are saying

  • The failure of the lupus drug brepocitinib in Phase 2 trials underscores the inherent risks in drug development and potential setbacks.
  • Rumors of acquiring Immunovant, Inc. could lead to financial strain and integration challenges if not managed properly.

What makes Roivant Sciences unique

  • Roivant Sciences leverages a unique business model that combines in-house product development with strategic partnerships, setting it apart from traditional biopharmaceutical companies.
  • The company's focus on RNA therapeutics and genetic disorders, particularly through its subsidiary Genevant, positions it at the forefront of cutting-edge medical treatments.
  • Roivant's ability to rapidly advance its drug pipeline and form strategic alliances allows it to bring innovative treatments to market more quickly and efficiently than many competitors.

Help us improve and share your feedback! Did you find this helpful?